227 related articles for article (PubMed ID: 24492450)
1. Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Chang YS; Chen HL; Hsu CY; Tang SH; Liu CK
J Clin Neurophysiol; 2014 Feb; 31(1):81-5. PubMed ID: 24492450
[TBL] [Abstract][Full Text] [Related]
2. Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
Vaitkevičius A; Kaubrys G; Audronytė E
Med Sci Monit; 2015 Jul; 21():1920-7. PubMed ID: 26138001
[TBL] [Abstract][Full Text] [Related]
3. The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
Reeves RR; Struve FA; Patrick G; Booker JG; Nave DW
Am J Geriatr Psychiatry; 1999; 7(4):349-52. PubMed ID: 10521169
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Werber AE; Klein C; Rabey JM
Neurol Neurochir Pol; 2001; 35 Suppl 3():37-43. PubMed ID: 12001652
[TBL] [Abstract][Full Text] [Related]
5. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
6. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Thomas A; Iacono D; Bonanni L; D'Andreamatteo G; Onofrj M
Clin Neuropharmacol; 2001; 24(1):31-42. PubMed ID: 11290880
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease.
Katada E; Sato K; Sawaki A; Dohi Y; Ueda R; Ojika K
J Geriatr Psychiatry Neurol; 2003 Mar; 16(1):39-43. PubMed ID: 12641372
[TBL] [Abstract][Full Text] [Related]
9. The role of event-related potentials in cognitive decline in Alzheimer's disease.
Lai CL; Lin RT; Liou LM; Liu CK
Clin Neurophysiol; 2010 Feb; 121(2):194-9. PubMed ID: 20005164
[TBL] [Abstract][Full Text] [Related]
10. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
Mizuno S; Kameda A; Inagaki T; Horiguchi J
Psychiatry Clin Neurosci; 2004 Dec; 58(6):660-5. PubMed ID: 15601392
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychological correlates of the P300 in patients with Alzheimer's disease.
Lee MS; Lee SH; Moon EO; Moon YJ; Kim S; Kim SH; Jung IK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():62-9. PubMed ID: 22940475
[TBL] [Abstract][Full Text] [Related]
12. Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease.
Cancelli I; Cadore IP; Merlino G; Valentinis L; Moratti U; Bergonzi P; Gigli GL; Valente M
J Clin Neurophysiol; 2006 Oct; 23(5):421-5. PubMed ID: 17016152
[TBL] [Abstract][Full Text] [Related]
13. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
Paci C; Gobbato R; Carboni T; Sanguigni S; Santone A; Curatola L
Neurol Sci; 2006 Feb; 26(6):435-7. PubMed ID: 16601937
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
15. Serum adipokine levels modified by donepezil treatment in Alzheimer's disease.
Pákáski M; Fehér A; Juhász A; Drótos G; Fazekas OC; Kovács J; Janka Z; Kálmán J
J Alzheimers Dis; 2014; 38(2):371-7. PubMed ID: 23979024
[TBL] [Abstract][Full Text] [Related]
16. The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Werber EA; Gandelman-Marton R; Klein C; Rabey JM
J Neural Transm (Vienna); 2003 Jun; 110(6):659-69. PubMed ID: 12768361
[TBL] [Abstract][Full Text] [Related]
17. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
[TBL] [Abstract][Full Text] [Related]
18. Concentration of donepezil to the cognitive response in Alzheimer disease.
Yang YH; Chen CH; Chou MC; Li CH; Liu CK; Chen SH
J Clin Psychopharmacol; 2013 Jun; 33(3):351-5. PubMed ID: 23609381
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
20. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.
Maher-Edwards G; Dixon R; Hunter J; Gold M; Hopton G; Jacobs G; Hunter J; Williams P
Int J Geriatr Psychiatry; 2011 May; 26(5):536-44. PubMed ID: 20872778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
